The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more ...

Eli Lilly & Co. closed $177.18 short of its 52-week high ($972.53), which the company reached on August 22nd. Supported by ...

After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

The Endowment made the grants through the latest round of its Religion and Cultural Institutions Initiative, a national initiative launched in 2019 that is supporting efforts to improve the public ...